Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical FITC-adalimumab Molecular Endoscopy in Ulcerative Colitis
DRKS00014353Phase 2Recruiting
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in autoimmune colitis, sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Primary endpoints: Safety of topical FITC-adalimumab application and Predictive capacity of mTNF+ cell detection. Started Mar 2018; status: recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on DRKS00014353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00014353.